Print Page
Myeloproliferative Neoplasms
Lakeland Regional Medical Center
Clinical Trial # MC-JHTB:
- Oral study medication 2784544 for patients who have had previous treatment for their JAK2V617F mutation of their Myeloproliferative disease, Essential Thrombosis.
- Essential Thrombosis patients must have failed or were not tolerant to the standard treatment.
- Hydroxyurea is allowed as long as it is a stable dosage.
- Exclusions include, but are not limited to: Use of Coumadin, use of CYP3A4 metabolized drugs or history of a stem cell transplant.
